Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,553 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A higher CD34 + cell dose correlates with better event-free survival after KIR-ligand mismatched cord blood transplantation for childhood acute myeloid leukemia.
Ishida H, Kawahara Y, Tomizawa D, Okamoto Y, Hama A, Cho Y, Koh K, Koga Y, Yoshida N, Sato M, Terui K, Miyagawa N, Watanabe A, Takita J, Kobayashi R, Yamamoto M, Watanabe K, Okada K, Kato K, Matsumoto K, Hino M, Tabuchi K, Sakaguchi H. Ishida H, et al. J Hematol Oncol. 2024 Apr 29;17(1):24. doi: 10.1186/s13045-024-01548-3. J Hematol Oncol. 2024. PMID: 38679709 Free PMC article.
Prognostic factors of children and adolescents with T-cell acute lymphoblastic leukemia after allogeneic transplantation.
Ishida H, Kato M, Kawahara Y, Ishimaru S, Najima Y, Kako S, Sato M, Hiwatari M, Noguchi M, Kato K, Koh K, Okada K, Iwasaki F, Kobayashi R, Igarashi S, Saito S, Takahashi Y, Sato A, Tanaka J, Hashii Y, Atsuta Y, Sakaguchi H, Imamura T. Ishida H, et al. Hematol Oncol. 2022 Aug;40(3):457-468. doi: 10.1002/hon.2980. Epub 2022 Mar 3. Hematol Oncol. 2022. PMID: 35212019
Impact of KIR-ligand mismatch on pediatric T-cell acute lymphoblastic leukemia in unrelated cord blood transplantation.
Kawahara Y, Ishimaru S, Tanaka J, Kako S, Hirayama M, Kanaya M, Ishida H, Sato M, Kobayashi R, Kato M, Goi K, Saito S, Koga Y, Hashii Y, Kato K, Sato A, Atsuta Y, Sakaguchi H. Kawahara Y, et al. Among authors: ishida h. Transplant Cell Ther. 2022 Sep;28(9):598.e1-598.e8. doi: 10.1016/j.jtct.2022.05.037. Epub 2022 Jun 1. Transplant Cell Ther. 2022. PMID: 35660064 Free article.
Optimizing transplantation procedures through identification of prognostic factors in second remission for children with acute myeloid leukemia with no prior history of transplant.
Ishida H, Tsujimoto SI, Hasegawa D, Sakaguchi H, Yamamoto S, Yanagimachi M, Koh K, Watanabe A, Hama A, Cho Y, Watanabe K, Noguchi M, Takeuchi M, Takita J, Washio K, Kato K, Koike T, Hashii Y, Tabuchi K, Hino M, Atsuta Y, Okamoto Y. Ishida H, et al. Haematologica. 2024 Jan 1;109(1):312-317. doi: 10.3324/haematol.2023.283203. Haematologica. 2024. PMID: 37470138 Free PMC article. No abstract available.
Reduced-intensity allogenic transplantation for children and adolescents with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Ishida H, Arakawa Y, Hasegawa D, Usami I, Hashii Y, Arai Y, Nishiwaki S, Keino D, Kato K, Sato M, Yoshida N, Ozawa Y, Okada K, Hidaka M, Yuza Y, Tanaka M, Watanabe K, Takita J, Kosaka Y, Fujita N, Tanaka J, Sato A, Atsuta Y, Imamura T. Ishida H, et al. Ann Hematol. 2024 Mar;103(3):843-854. doi: 10.1007/s00277-023-05557-z. Epub 2023 Nov 25. Ann Hematol. 2024. PMID: 38006571
JACLS ALL-02 SR protocol reduced-intensity chemotherapy produces excellent outcomes in patients with low-risk childhood acute lymphoblastic leukemia.
Takahashi Y, Ishida H, Imamura T, Tamefusa K, Suenobu S, Usami I, Yumura-Yagi K, Hasegawa D, Nishimura S, Suzuki N, Hashii Y, Deguchi T, Moriya-Saito A, Kosaka Y, Kato K, Kobayashi R, Kawasaki H, Hori H, Sato A, Kudo T, Nakahata T, Oda M, Hara J, Horibe K. Takahashi Y, et al. Among authors: ishida h. Int J Hematol. 2022 Jun;115(6):890-897. doi: 10.1007/s12185-022-03315-x. Epub 2022 Mar 8. Int J Hematol. 2022. PMID: 35258855
Allogeneic stem cell transplantation for children and adolescents/young adults with de novo blastic phase chronic myeloid leukemia in the tyrosine kinase inhibitor era.
Ishida H, Shimada H, Tanizawa A, Shimazu Y, Tachibana T, Doki N, Ara T, Matsuo Y, Nara M, Toubai T, Ino K, Nakamae H, Kato K, Kato K, Sato A, Hino M, Matsumoto K, Atsuta Y, Yasui M, Nagamura-Inoue T. Ishida H, et al. Am J Hematol. 2023 Aug;98(8):E200-E203. doi: 10.1002/ajh.26959. Epub 2023 May 12. Am J Hematol. 2023. PMID: 37170859
Low Incidence of Osteonecrosis in Childhood Acute Lymphoblastic Leukemia Treated With ALL-97 and ALL-02 Study of Japan Association of Childhood Leukemia Study Group.
Sakamoto K, Imamura T, Kihira K, Suzuki K, Ishida H, Morita H, Kanno M, Mori T, Hiramatsu H, Matsubara K, Terui K, Takahashi Y, Suenobu SI, Hasegawa D, Kosaka Y, Kato K, Moriya-Saito A, Sato A, Kawasaki H, Yumura-Yagi K, Hara J, Hori H, Horibe K. Sakamoto K, et al. Among authors: ishida h. J Clin Oncol. 2018 Mar 20;36(9):900-907. doi: 10.1200/JCO.2017.75.5066. Epub 2018 Jan 23. J Clin Oncol. 2018. PMID: 29360413
3,553 results